Latest PEG ratio for Paratek Pharmaceuticals: 10.95 — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow10.95
The PEG ratio measures a stock's valuation relative to its earnings growth rate. A PEG ratio below 1.0 may indicate that the stock is undervalued relative to its growth potential.
Paratek Pharmaceuticals's peg ratio stands at 10.95. That is above the Healthcare sector average of 3.22. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.
Paratek Pharmaceuticals sits higher the Healthcare benchmark (3.22) with a PEG ratio of 10.95. That is roughly 239.9% above the sector mean. Peer context matters because what looks expensive or cheap in absolute terms can be normal for the sector.
Whether 10.95 is attractive depends on Paratek Pharmaceuticals's earnings outlook, competitive position, and how peers are valued. Investors typically ask: is growth accelerating, are margins stable, and is the multiple expanding or compressing over time? The history and comparison charts below are built for those checks.
The history chart shows how Paratek Pharmaceuticals's PEG ratio evolved across reporting periods, while the comparison chart places PRTK next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.
Yes — within Healthcare, PEG ratio is commonly used to spot outliers. Paratek Pharmaceuticals's reading of 10.95 (sector avg 3.22) is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.